drug
(cobicistat + darunavir + emtricitabine + tenofovir alafenamide)
Marketedupdated 3mo agoby $JNJ JOHNSON & JOHNSON
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (cobicistat + darunavir + emtricitabine + tenofovir alafenamide)
- phase3The Late Presenter Treatment Optimisation Study
- phase4Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
- phase3Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
- phase4Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 26, 2026
133 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jul 19, 2038method-of-use (U-2978)US 10786518
- Oct 6, 2032formulationUS 10039718
- Aug 15, 2032compositionUS 8754065
- Aug 15, 2032compositionUS 9296769
- Sep 3, 2029compositionUS 81483743.1y
- Dec 26, 2026compositionUS 7700645133d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that